Nuvectis Pharma, Inc. — Director's Dealing 2022

Apr 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-04-01

Reporting Person: Kaplan Matthew L. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-01	Stock Options (right to buy)	$7.02	A	15000	Acquired	2032-04-01	Common Stock (15000)	Direct

Footnotes

F1: The options will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025.